Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$28.68M$28.68M−37.8% vs Q2 2019 Net Income-$8.68M-$8.68MN/M vs Q2 2019 EPS Diluted-$0.23-$0.23N/M vs Q2 2019 Operating Income-$8,981,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$23,083,000N/M Margins · derivedOperating margin-31.3%−51.3 pt vs Q2 2019
Net margin-30.3%−54.5 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 10, 2020 · 41 d after period end